Efficacy and Safety of Ostenil® Plus in the Treatment of Coxarthrosis
- Conditions
- Coxarthrosis
- Interventions
- Device: Ostenil® Plus
- Registration Number
- NCT03809962
- Lead Sponsor
- TRB Chemedica AG
- Brief Summary
PMCF study to observe the Routine application of Ostenil® Plus in the Treatment of pain and restricted mobility in degenerative and traumatic changes of the Hip Joint.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 250
- Subjects ≥ 18 years of age and in good general health condition
- Signed informed consent
- Existing Ostenil® Plus recommendation for the treatment of coxarthrosis
- Known hypersensitivity to one of the OSTENIL® PLUS components
- Known pregnancy or lactating females
- Previous/concomitant participation in clinical investigation within the last 3 months prior to study inclusion
- Subjects not capable of contracting and of understanding the nature, risks, significance and implications of the clinical investigation and unable to form a rational intention in the light of these facts
- Subjects unable to understand informed consent or having a high probability of non compliance to the study procedures and / or non completion of the study according to investigator's judgement (e.g. illiteracy, insufficient knowledge of local language)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Ostenil® Plus Ostenil® Plus 1-3 injections of sodium hyaluronate 2% (40 milligrams (mg) / 2,0 millilitres (ml)) in weekly interval.
- Primary Outcome Measures
Name Time Method Change of Subjective Symptom Evaluation (Overall Impression on a scale from 1 to 5) Day 7, Day 14, Day 84 after last injection, Day 168 after last injection The Change of Overall Subjective Symptom Evaluation on a scale from 1 (much improved) to 5 (much worse).
Change of Subjective Therapy Evaluation of Stiffness (HOOS Questionnaire) compared to Baseline Day 84 after last injection, Day 168 after last injection Hip Disability and Osteoarthritis Outcome Score (HOOS) to assess Stiffness on a 5-point Likert scale
Change of Subjective Therapy Evaluation of Quality of Life (HOOS Questionnaire) compared to Baseline Day 84 after last injection, Day 168 after last injection Hip Disability and Osteoarthritis Outcome Score (HOOS) to assess Quality of Life on a 5-point Likert scale
Change of Pain Intensity compared to Baseline (VAS-slider) Day 7, Day 14, Day 84 after last injection, Day 168 after last injection Evaluation of Pain Intensity by the Patient on a 10 cm VAS-slider (10 cm equals the most pain)
Change of Subjective Therapy Evaluation of Pain (HOOS Questionnaire) compared to Baseline Day 84 after last injection, Day 168 after last injection Hip Disability and Osteoarthritis Outcome Score (HOOS) to assess Pain on a 5-point Likert scale
Change of Range of Motion compared to Baseline (Goniometer measurement) Day 7, Day 14, Day 84 after last injection, Day 168 after last injection Assessment of the Range of internal and exernal rotation of the Hip Joint using a Goniometer.
Incidence of Treatment-Emergent Adverse Events Up to Day 252 after the last injection Change of Subjective Therapy Evaluation of Function in daily living (HOOS Questionnaire) compared to Baseline Day 84 after last injection, Day 168 after last injection Hip Disability and Osteoarthritis Outcome Score (HOOS) to assess Function in daily living on a 5-point Likert scale
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
Gemeinschaftspraxis für Orthopädie und Unfallchirurgie
🇩🇪Bad Oldesloe, Schleswig-Holstein, Germany
Orthopraxis Kiel
🇩🇪Gettorf, Schleswig-Holstein, Germany
Zentrum für Medizin des Bewegungsapparates
🇩🇪Heide, Schleswig-Holstein, Germany
Orthopädische Praxis Rahlstedt
🇩🇪Hamburg, Germany
Orthopädie Praxis
🇩🇪Ramelsloh, Germany
OrthopädieZentrum Maschen
🇩🇪Seevetal, Germany
Orthopädische Gemeinschaftspraxis Eutin
🇩🇪Eutin, Germany